Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU028481

MISSION® esiRNA

targeting human GABRP

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

AGATCAGCTTTGCCAGCATTGAAATTTCCAGCGACAACGTTGACTACAGTGACTTGACAATGAAAACCAGCGACAAGTTCAAGTTTGTCTTCCGAGAAAAGATGGGCAGGATTGTTGATTATTTCACAATTCAAAACCCCAGTAATGTTGATCACTATTCCAAACTACTGTTTCCTTTGATTTTTATGCTAGCCAATGTATTTTACTGGGCATACTACATGTATTTTTGAGTCAATGTTAAATTTCTTGCATGCCATAGGTCTTCAACAGGACAAGATAATGATGTAAATGGTATTTTAGGCCAAGTGTGCACCCACATCCAATGGTGCTACAAGTGACTGAAATAATATTTGAGTCTTTCTGCTCAAAGAATGAAGCTCCAACCATTGTTCTAAGCTGTGTAGAAGTCCTAGCATTATAGGATCTTGTAATAGAAACATCAGTCCATTCCTCTTTCATCTTAATCAAGGACATTCCCATGGA

Ensembl | human accession no.

ENSG00000094755

NCBI accession no.

NM_014211

shipped in

ambient

storage temp.

−20°C

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
THU
CRT
QCS

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vikram B Wali et al.
Scientific reports, 9(1), 14934-14934 (2019-10-19)
The goal of this study was to identify a novel target for antibody-drug conjugate (ADC) development in triple negative breast cancer (TNBC), which has limited treatment options, using gene expression datasets and in vitro siRNA/CRISPR and in vivo functional assays.

Global Trade Item Number

SKUGTIN
EHU028481-20UG04061831350340
EHU028481-50UG04061831371444